The report will be delivered in 2-3 business days.

Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change

Starting Price : $ 4000.00 $3200.00 | Pages : 150 | Published : October 2020 | SKU CODE : 7730 | Format :


The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs.

The global cancer monoclonal antibodies market is expected to decline from $48.36 billion in 2019 to $45.40 billion in 2020 at a compound annual growth rate (CAGR) of -6.13%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $61.15 billion in 2023 at a CAGR of 10.44%.

North America was the largest region in the cancer monoclonal antibodies market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market.

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to The American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states. Thus, the high development costs in using these advanced techniques will restrain market growth.

Companies in the cancer monoclonal antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In September 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies for cancer.

In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University.

The major players covered in the global cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., Spectrum Pharmaceuticals, Seattle Genetics, Pfizer, Sanofi, Abbvie,  Takeda Pharmaceuticals, Genentech,  AstraZeneca,  Biogen.

The countries covered in the global cancer monoclonal antibodies market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global cancer monoclonal antibodies market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global cancer monoclonal antibodies market is segmented - 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others. 2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others.

    1. Executive Summary

    2. Cancer Monoclonal Antibodies (mAbs) Market Characteristics

    3. Cancer Monoclonal Antibodies (mAbs) Market Size And Growth

    3.1. Global Cancer Monoclonal Antibodies (mAbs) Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Cancer Monoclonal Antibodies (mAbs) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Cancer Monoclonal Antibodies (mAbs) Market Segmentation

    4.1. Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Bevacizumab (Avastin)

    Rituximab (Rituxan)

    Trastuzumab (Herceptin)

    Cetuximab (Erbitux)

    Panitumumab (Vectibix)

    Others

    4.2. Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Breast Cancer

    Blood Cancer

    Liver Cancer

    Brain Cancer

    Colorectal Cancer

    Others

    5. Cancer Monoclonal Antibodies (mAbs) Market Regional And Country Analysis

    5.1. Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Cancer Monoclonal Antibodies (mAbs) Market

    6.1. Asia-Pacific Cancer Monoclonal Antibodies (mAbs) Market Overview

    6.2. Asia-Pacific Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Cancer Monoclonal Antibodies (mAbs) Market

    7.1. China Cancer Monoclonal Antibodies (mAbs) Market Overview

    7.2. China Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Cancer Monoclonal Antibodies (mAbs) Market

    8.1. India Cancer Monoclonal Antibodies (mAbs) Market Overview

    8.2. India Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Cancer Monoclonal Antibodies (mAbs) Market

    9.1. Japan Cancer Monoclonal Antibodies (mAbs) Market Overview

    9.2. Japan Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Cancer Monoclonal Antibodies (mAbs) Market

    10.1. Australia Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Cancer Monoclonal Antibodies (mAbs) Market

    11.1. Indonesia Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Cancer Monoclonal Antibodies (mAbs) Market

    12.1. South Korea Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Cancer Monoclonal Antibodies (mAbs) Market

    13.1. Western Europe Cancer Monoclonal Antibodies (mAbs) Market Overview

    13.2. Western Europe Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Cancer Monoclonal Antibodies (mAbs) Market

    14.1. UK Cancer Monoclonal Antibodies (mAbs) Market Overview

    14.2. UK Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Cancer Monoclonal Antibodies (mAbs) Market

    15.1. Germany Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Cancer Monoclonal Antibodies (mAbs) Market

    16.3. France Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Cancer Monoclonal Antibodies (mAbs) Market

    17.1. Eastern Europe Cancer Monoclonal Antibodies (mAbs) Market Overview

    17.2. Eastern Europe Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Cancer Monoclonal Antibodies (mAbs) Market

    18.1. Russia Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Cancer Monoclonal Antibodies (mAbs) Market

    19.1. North America Cancer Monoclonal Antibodies (mAbs) Market Overview

    19.2. North America Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Cancer Monoclonal Antibodies (mAbs) Market

    20.1. USA Cancer Monoclonal Antibodies (mAbs) Market Overview

    20.2. USA Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Cancer Monoclonal Antibodies (mAbs) Market

    21.1. South America Cancer Monoclonal Antibodies (mAbs) Market Overview

    21.2. South America Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Cancer Monoclonal Antibodies (mAbs) Market

    22.1. Brazil Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Cancer Monoclonal Antibodies (mAbs) Market

    23.1. Middle East Cancer Monoclonal Antibodies (mAbs) Market Overview

    23.2. Middle East Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Cancer Monoclonal Antibodies (mAbs) Market

    24.1. Africa Cancer Monoclonal Antibodies (mAbs) Market Overview

    24.2. Africa Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Cancer Monoclonal Antibodies (mAbs) Market Competitive Landscape And Company Profiles

    25.1. Cancer Monoclonal Antibodies (mAbs) Market Competitive Landscape

    25.2. Cancer Monoclonal Antibodies (mAbs) Market Company Profiles

    25.2.1. Amgen

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Bristol Myers Squibb Company

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Eli Lilly and Company

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. F. Hoffmann-La Roche Ltd

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Genmab AS

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies (mAbs) Market

    27. Cancer Monoclonal Antibodies (mAbs) Market Trends And Strategies

    28. Cancer Monoclonal Antibodies (mAbs) Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: China, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: India, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: Japan, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: Australia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: Indonesia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: South Korea, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Western Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: UK, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Germany, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: France, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Eastern Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Russia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: North America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: USA, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: South America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: Brazil, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: Middle East, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Africa, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Amgen Financial Performance
  • Table 27: Bristol Myers Squibb Company Financial Performance
  • Table 28: Eli Lilly and Company Financial Performance
  • Table 29: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 30: Genmab AS Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: China, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: India, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: Japan, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: Australia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: Indonesia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: South Korea, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Western Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: UK, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Germany, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: France, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Eastern Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Russia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: North America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: USA, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: South America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: Brazil, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: Middle East, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Africa, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Amgen Financial Performance
  • Figure 27: Bristol Myers Squibb Company Financial Performance
  • Figure 28: Eli Lilly and Company Financial Performance
  • Figure 29: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 30: Genmab AS Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)